World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
44507
World Ranking
9900
National Ranking
5094

Corey J. Langer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Corey J. Langer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 687 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Corey J. Langer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Corey J. Langer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Corey J. Langer is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the field of medicine, with an emphasis on pulmonary and respiratory medicine and oncology.

Their work covers several subfields, including:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Immunology

Corey J. Langer focuses on multiple research topics, such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Occupational and environmental lung diseases

Frequent venues where Langer has published include:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Clinical Lung Cancer
  • Journal of Thoracic Oncology
  • JTO Clinical and Research Reports

Corey J. Langer has collaborated extensively with several coauthors, including:

  • Roger B. Cohen
  • Charu Aggarwal
  • Melina E. Marmarelis
  • Lova Sun
  • Aditi P. Singh

Selected recent papers authored or coauthored by Langer illustrate a focus on lung cancer and immunotherapy. These include:

  • "Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial," 2020, Annals of Oncology
  • "Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407," 2021, Journal of Thoracic Oncology
  • "Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC," 2020, Journal of Thoracic Oncology
  • "Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients," 2024, Science
  • "Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer," 2020, JAMA Oncology

Best Publications

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

    Andy Trotti;A.Dimitrios Colevas;Ann Setser;Valerie Rusch

  • Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

    Walter J. Curran;Rebecca Paulus;Corey J. Langer;Ritsuko Komaki

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival

    Henry T. Hoffman;Kimberly Porter;Lucy H. Karnell;Jay S. Cooper

  • Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

    Nasser Hanna;Paul A. Bunn;Corey Langer;Lawrence Einhorn

  • Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

    Corey J. Langer;Judith Manola;Patricia Bernardo;John W. Kugler

  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

    Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • National Cancer Database report on cancer of the head and neck: 10-year update

    Jay S. Cooper;Kim Porter;Katherine Mallin;Henry T. Hoffman

  • Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

    Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  • Current management of brain metastases, with a focus on systemic options

    Corey J. Langer;Minesh P. Mehta

  • Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

    Stephen J. Bagley;Shawn Kothari;Charu Aggarwal;Joshua M. Bauml

  • Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410

    W Curran;C Scott;C Langer;R Komaki

  • Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911

    Corey J. Langer;Jonathan Harris;Eric M. Horwitz;Nicos Nicolaou

  • Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

    Charu Aggarwal;Jeffrey C. Thompson;Taylor A. Black;Sharyn I. Katz

  • Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

    Daniel D. Karp;Luis G. Paz-Ares;Silvia Novello;Paul Haluska

  • The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

    Corey J. Langer;Benjamin Besse;Antonio Gualberto;Elizabeth Brambilla

  • Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

    Scott N Gettinger;Lyudmila A Bazhenova;Corey J Langer;Ravi Salgia

Frequent Co-Authors

Benjamin Movsas
Benjamin Movsas Henry Ford Health System
Scott N. Gettinger
Scott N. Gettinger Yale University
Walter J. Curran
Walter J. Curran Emory University
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Alice T. Shaw
Alice T. Shaw Harvard University
David R. Gandara
David R. Gandara University of California, Davis
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Ritsuko Komaki
Ritsuko Komaki The University of Texas MD Anderson Cancer Center
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens various alternative and supportive roles beyond the traditional MD route. Many students explore online pathways in nursing and healthcare due to their flexibility and affordability.

If you're drawn to advanced practice nursing, pursuing the cheapest np school online can lead to a Nurse Practitioner role, which is both in high demand and impactful. For those wanting to advance as leaders or educators in nursing, enrolling in one of the phd nursing education online programs can open doors to academic or research-oriented careers.

Registered Nurses (RNs) looking to expand their credentials can benefit from the cheapest rn to bsn online programs, which provide a cost-effective and flexible route to a Bachelor of Science in Nursing. Likewise, professionals seeking a master's degree can find value in the cheapest online msn programs, making graduate education more accessible.

Exploring these affordable and flexible online degrees can help aspiring healthcare professionals find the right fit for their goals and budgets while contributing meaningfully to the medical field.

Best Scientists Citing Corey J. Langer

Trending Scientists

Recently Published Articles